Literature DB >> 1851831

Bradykinin-stimulated inositol phosphate production in NG108-15 cells is mediated by a small population of binding sites which rapidly desensitize.

D H Wolsing1, J S Rosenbaum.   

Abstract

[3H]Bradykinin (BDK) binds to two distinct binding sites (P less than .01, N = 12) in NG108-15 cell membranes; (site 1: Kd1 = 3.09 x 10(-10) M, Bmax1 = 242 +/- 24 fmol/mg protein) and (site 2: Kd2 = 1.94 x 10(-8) M, Bmax2 = 491 +/- 75 fmol/mg protein). Although site 1 comprises only 33 +/- 4% (N = 12) of the total binding site population, comparison of the binding affinity and functional potency for BDK agonist analogs exhibiting differential selectivity for the two sites reveals that this high affinity site is the receptor mediating inositol monophosphate (IP) production in this cell line. BDK-stimulated IP production undergoes a very rapid (5 min) desensitization that is characterized by both a loss in agonist potency (EC50 = 3.57 x 10(-9) M vs. 1.94 x 10(-10) M in controls; P less than .001, N = 12) and a decrease in amplitude of response (fold stimulation = 1.45 +/- 0.06 vs. 1.80 +/- 0.09 in controls; P less than .01, N = 12). Only the decrease in response amplitude is attenuated by down-regulation of protein kinase C by prior long term treatment of the cells with 12-O-tetradecanoylphorbol 13-acetate (TPA), indicating an involvement of protein kinase C activation in the desensitization process. Desensitization is accompanied by down-regulation of site 1 only (Bmax1 = 71 +/- 8 fmol/mg (N = 10; P less than .001 vs. controls)); Bmax2 and the Kd for BDK at both sites remain unchanged, further supporting the contention that site 1 is the functionally relevant receptor. In contrast to the functional data, long term TPA treatment does not attenuate the receptor down-regulation, indicating that the rapid desensitization involves both receptor-related and postreceptor mechanisms. The implications of this property of the BDK receptor for analog design and receptor classification are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851831

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins.

Authors:  T A Fields; P J Casey
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

2.  Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway.

Authors:  S Isami; H Kishikawa; E Araki; M Uehara; K Kaneko; T Shirotani; M Todaka; S Ura; S Motoyoshi; K Matsumoto; N Miyamura; M Shichiri
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

3.  Cyclic GMP regulates activation of phosphoinositidase C by bradykinin in sensory neurons.

Authors:  J S Harvey; G M Burgess
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

4.  Kinin-induced chloride permeability changes in colony 29 epithelia estimated from 125I- efflux and MEQ fluorescence.

Authors:  L J MacVinish; T Reancharoen; A W Cuthbert
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

5.  Quantitative comparisons of muscarinic and bradykinin receptor-mediated Ins (1,4,5)P3 accumulation and Ca2+ signalling in human neuroblastoma cells.

Authors:  G B Willars; S R Nahorski
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptor.

Authors:  J S Davidson; I K Wakefield; R P Millar
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

7.  Raf kinase inhibitory protein reduces bradykinin receptor desensitization.

Authors:  Samuel B Chivers; Allison Doyle Brackley; Nathaniel A Jeske
Journal:  J Neurochem       Date:  2022-05-08       Impact factor: 5.546

Review 8.  Pathophysiology and underlying mechanisms in hereditary angioedema.

Authors:  Alberto López Lera
Journal:  Balkan Med J       Date:  2021-03       Impact factor: 2.021

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.